Diocor

Quick links to important sections

Diocor

Method of action: Diuretic

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diocor

What is Diocor? Foundational Drug Identity

Property Description
Active ingredient Furosemide, Spironolactone
Form Solid preparation (Oral Tablets)
Pharmacological class Diuretics (Loop Diuretic + Potassium-Sparing Diuretic)
Common purpose Elimination of excess fluid and sodium
Origin Synthetic

Diocor is a prescription-only synthetic combination diuretic preparation administered as an oral tablet that incorporates two distinct active pharmaceutical ingredients to manage fluid and electrolyte balance in the body. It belongs to the high-level pharmacological class of Diuretics (or "water pills"), a category of compounds used to promote the elimination of unneeded fluid from the circulatory system and body tissues. This combination is widely recognized in clinical practice for addressing conditions characterized by significant fluid overload.

What Type of Medicine is Diocor? Classification and Origin

Diocor is classified as a dual-action agent, combining a potent loop diuretic (Furosemide) with a potassium-sparing diuretic (Spironolactone). Both active substances are chemically synthetic entities. This dual-action formula is an intentional design choice, distinguishing it from single-agent diuretics; the combination is clinically recognized for its ability to produce substantial fluid excretion while simultaneously offering better control over potassium levels compared to Furosemide alone. This formulation is used generically worldwide and is marketed under various trade names, including Lasilactone and Spiromide.

Active Ingredients and Dual-Action Formula

The core composition includes Furosemide and Spironolactone. Furosemide is the highly effective component that rapidly promotes the elimination of sodium and water from the kidneys. Spironolactone functions as a mineralocorticoid receptor antagonist, blocking the effects of the hormone aldosterone that naturally promotes sodium retention. This synergistic approach is designed to improve fluid management compared to single-agent therapy. The combination helps enhance the body's ability to excrete fluid while managing necessary minerals.

Diocor's General Purpose: Management of Fluid Balance

The general purpose of this combination preparation is to promote controlled and highly effective diuresis for the overall maintenance of electrolyte balance. By successfully increasing the excretion of accumulated excess water and sodium, Diocor reduces the total fluid volume in the body. This process aims to lessen the physical and circulatory strain resulting from fluid overload or edema (swelling), a typical scenario in patients requiring rigorous fluid management.

What side effects are possible with Diocor?

Possible Side Effects and Safety Information

Regulatory documents classify the possible side effects and safety characteristics of this combination diuretic preparation based on incidence and the affected physiological system. The safety profile is heavily defined by the medication's intended action on fluid and electrolyte balance.

Official Adverse Reaction Classification

Adverse reactions are formally categorized based on the frequency documented in clinical data and post-marketing surveillance, consistent with international regulatory standards:

  • Very Common: Disturbances of fluid and electrolyte balance, including Hypokalemia, Hyperkalemia, and conditions related to volume loss such as Dehydration.
  • Common: Reactions such as Nausea, Headache, and Dizziness.
  • Uncommon: Certain dermatological reactions or manifestations of Ototoxicity (hearing impairment or tinnitus).
  • Rare: Serious adverse events including severe hypersensitivity reactions (e.g., Anaphylaxis) and blood cell disorders like Agranulocytosis.

These effects are grouped into System-Organ Classes (SOC), which cover Metabolism and Nutrition disorders, Nervous System disorders, Renal and Urinary disorders, and, for the Spironolactone component, Reproductive system and Breast disorders (e.g., Gynecomastia).

Serious Adverse Reactions and Constraints

Officially documented serious adverse reactions include the risk of Severe Hypersensitivity Reactions, Ototoxicity, and the potential to precipitate Hepatic Encephalopathy in patients with pre-existing severe liver impairment. Safety regulations specify that the risk of Hyperkalemia may increase with longer duration of treatment. The medication is formally contraindicated in patients with conditions such as Anuria, Addison’s disease, and pre-existing severe Hyperkalemia or Severe renal impairment, as defined in the official regulatory labeling.

Overdose and Emergency Response

The regulatory profile for a Diocor overdose is centered on the consequences of its dual diuretic action, primarily massive fluid and volume depletion and severe electrolyte and metabolic derangement. Overdose manifestations documented in official labeling include Hypotension, Dehydration, Lethargy, and significant imbalances such as Hypokalemia or Hyperkalemia. Patients may experience systemic signs like severe weakness, Drowsiness, Mental Confusion, and gastrointestinal distress. The Furosemide component also introduces the potential for Tinnitus or Hearing Loss.

Overdose can lead to severe, life-threatening outcomes. These include Cardiac Arrhythmias stemming from electrolyte instability, Circulatory Collapse, and Vascular Thrombosis and Embolism due to hemoconcentration. In patients with pre-existing conditions, overdose may precipitate Hepatic Encephalopathy or acute Renal Failure.

Immediate medical attention must be sought for any suspected overdose or upon the manifestation of signs indicating excessive fluid and/or electrolyte losses. The official management involves Symptomatic and Supportive Treatment aimed at correcting fluid balance and severe electrolyte abnormalities. Regulatory sources specify that no specific antidote is known for this combination preparation. Population-specific notes indicate that Elderly patients and those with hepatic or renal impairment face an increased risk of severe complications.

Therapeutic Uses of Diocor

The therapeutic uses of Diocor, a combination of Furosemide and Spironolactone, are focused entirely on the clinical need to address excess fluid and sodium retention. This combination is considered relevant across therapeutic domains involving distressing fluid-driven symptoms, supporting controlled fluid removal and may assist with maintaining functional stability regarding potassium balance.

Clinical applications commonly include managing fluid retention associated with Congestive Heart Failure, Liver Cirrhosis, Nephrotic Syndrome, and certain types of Hypertension.

Managing Severe Swelling and Systemic Fluid Congestion

This medication is commonly used across conditions presenting with significant symptomatic burden related to fluid retention, such as pronounced edema in the extremities and ascites (abdominal fluid build-up). The medication helps provide supportive relief that helps ease the overall symptom load of symptoms related to physical discomfort and distension associated with persistent swelling.

“The medication helps provide supportive relief that helps patients cope more steadily with difficult episodes of fluid overload.”

Addressing Volume Overload and Complex Fluid Retention

Diocor plays a role in managing fluid volume in patients where excess fluid creates noticeable physiological strain. This formula is considered relevant for easing symptoms and supports potassium balance. It is also applied in clinical settings that involve acute or unstable symptom patterns, such as resistant edema. By reducing this volume, it helps alleviate symptoms of increased neurological or muscular activity, such as shortness of breath.


Quick Fact: Relief for Systemic Fluid Overload

Regulatory References

  1. NIH StatPearls overview on combination diuretics

Eligibility and Restrictions for Use

Eligibility for Diocor (Valsartan-Hydrochlorothiazide)

This medicine is not appropriate for all patients. Eligibility is strictly defined by government regulatory documents, focusing on patient status, comorbidities, and hypersensitivity.

Contraindicated Populations (Must NOT Use) Restricted or Conditional Use Populations
Pregnancy (Second and Third Trimesters) due to severe risk of fetal harm. Patients with severe renal impairment (creatinine clearance leq 30 mL/ min) and those with anuria (no urine production).
Patients with Anuria (no urine production). Patients with hepatic impairment (caution is required, and the medicine is contraindicated in severe impairment or biliary cirrhosis).
Patients with known hypersensitivity to any component or to sulfonamide-derived drugs. Pediatric patients (under 18 years of age); safety and effectiveness are not established.
Patients with diabetes mellitus who are concurrently taking aliskiren. Geriatric patients may be more sensitive to the drug's effects.

Pregnancy and Lactation Status: The medicine is contraindicated in the second and third trimesters. When pregnancy is detected, treatment must be discontinued immediately. Use while breastfeeding is not recommended as hydrochlorothiazide is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Diocor (Furosemide/Spironolactone) around combinations that present a significant risk of severe adverse outcomes or those that alter the drug's intended effect.

Contraindicated Combinations

Co-administration is strictly contraindicated with several substance categories due to the severe and additive risk of hyperkalemia (dangerously high potassium levels). These include Eplerenone, potassium supplements, and other potassium-sparing diuretics (such as Amiloride or Triamterene).

Clinically Significant Interactions

Interacting Substance/Class Official Interaction Outcome Constraint Type
Lithium Reduces renal clearance leading to increased toxicity risk. Pharmacokinetic
ACE Inhibitors/ARBs Increases risk of severe hyperkalemia due to additive effects. Pharmacodynamic
Aminoglycoside Antibiotics Increases risk of ototoxicity and nephrotoxicity (additive toxicity). Pharmacodynamic
NSAIDs Reduces diuretic and antihypertensive effects (antagonism). Pharmacodynamic
Sucralfate Must be separated by at least two hours to prevent reduced efficacy. Timing Requirement
Food Increases systemic bioavailability of the Spironolactone component. Exposure Modification

These official statements mandate specific restrictions and require temporal separation for certain co-administered substances to manage documented risks and maintain the expected regulatory profile.

Mechanism of Action

The mechanism of Diocor, a combination diuretic, is based on the Sequential Nephron Blockade principle, targeting two critical fluid-regulating sites in the kidney simultaneously, resulting in a dual increase in water and sodium excretion while modulating net potassium excretion.

Targeted Blockade of Renal Ion Transport

Both active components initiate molecular interactions within the kidney's tubular system. Furosemide acts with rapid kinetics by inhibiting the NKCC2 cotransporter in the Loop of Henle, preventing the reabsorption of a large fraction of filtered salt and water. Spironolactone's action is slower, operating by antagonizing the intracellular Mineralocorticoid Receptor ( MR) in the collecting duct, which prevents hormonal signaling for sodium retention. This combination initiates a high-volume, two-step natriuresis ( sodium excretion) cascade.

Sequential Mechanism and Electrolyte Modulation

This complementary mechanism addresses the body's fluid-regulation defenses. Furosemide's action induces compensatory fluid-retention mechanisms, but Spironolactone's MR antagonism blocks this counter-regulation in the distal nephron, thereby maintaining the increased rate of natriuresis. Furthermore, the potassium- losing consequence of Furosemide is offset by the potassium- sparing effect of Spironolactone, resulting in potassium conservation during extracellular fluid volume ( ECFV) reduction.

Dosage and Administration Information

How Diocor is Used: Official Administration Guidelines

Diocor, the combination of Furosemide and Spironolactone, is administered through the oral route as a solid tablet formulation. Its procedural use is defined by specific administration criteria.


Administration Conditions and Dosing

The medication is generally reserved for managing fluid retention that is refractory to treatment with a single diuretic agent alone, signifying its context as a specialized regimen. The tablets must be swallowed whole with liquid and should not be crushed, cut, or chewed.

The recommended starting dose for adults typically begins with one tablet daily. The maintenance dosage is then adjusted based on the required effect, generally ranging from one to four tablets daily. This regimen delivers Furosemide from 20 mg to 80 mg and Spironolactone from 50 mg to 200 mg. The prescribed daily dose may be given as a single administration or split into divided doses.


Timing and Special Constraints

To align with the expected diuretic action and avoid sleep disruption, the tablets should be taken with meals, preferably during breakfast or lunch. It is a critical instruction that the final dose of the day must not be taken in the late afternoon or evening.

Specific clinical constraints apply to certain populations: the fixed-dose combination product is not suitable for use in children. For older adults, caution is required, and a slower dose titration may be necessary due to the potential for slower excretion. Additionally, the proper administration of this medicine requires regular monitoring of serum electrolytes, including potassium and sodium, as well as kidney function (creatinine), to safely manage the ongoing dosage.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diocor


Evidence for Use in Congestive Heart Failure and Fluid Congestion

Research has focused on the Furosemide/Spironolactone combination to explore the management of fluid overload, known as congestion, in adult patients, particularly those with Chronic Heart Failure (CHF). Research in this area primarily includes Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies have primarily monitored clinical endpoints, such as the rates of hospitalization for heart events and changes in a patient's functional status.

Findings describe patterns observed in the studies related to the management of fluid volume in patients with severe congestion. When compared to the use of Furosemide alone, the combination was evaluated for outcomes related to systemic or functional imbalance, such as changes in serum potassium balance, which is monitored in research focusing on heart and muscle function.

Data show patterns related to fluid removal, but the results apply only to the populations studied. Certainty remains low regarding the optimal approach for patients who display symptoms of diuretic resistance (where the fluid removal response is insufficient). Furthermore, follow-up durations were limited in some trials, meaning that long-term effects are not fully established regarding the durability of fluid management.


Evidence for Management of Ascites and Edema Secondary to Liver Disease

Research has focused on the Furosemide/Spironolactone combination to explore the management of fluid retention, specifically ascites (fluid build-up in the abdomen) and swelling (edema) often associated with Liver Cirrhosis. Research in this area includes comparative Randomized Controlled Trials that examined treatment using the combination versus using Spironolactone alone. Studies monitored the pace at which accumulated fluid could be safely removed, recording data related to overall weight loss and the time required for ascites to resolve.

Studies documented observed patterns of fluid mobilization, and studies monitored physiological strain or stress, particularly tracking electrolyte levels. Findings contribute to contextualizing how patients reported their experience during fluid removal. Comparative evidence is lacking regarding which regimen leads to the most stable long-term outcome.

Frequently Asked Questions (FAQ)

Common questions about Diocor (FAQ)


Q: How quickly does Diocor usually start to work?

Regulatory documents indicate that the furosemide component of Diocor begins to promote fluid elimination, or diuresis, often within one hour of being taken orally. The diuretic effect is generally observed to complete within about six to eight hours. The spironolactone component, however, has an action that is more gradual and sustained over time.


Q: What happens if I forget to take Diocor for a day?

Official guidance states that a missed dose may be taken if the time difference is appropriate. If it is already close to the time for the next scheduled dose, the missed dose is typically skipped. Product information specifies that double doses should not be taken to make up for a missed dose.


Q: Are there any common foods or drinks to avoid while taking Diocor?

Due to the spironolactone component, there is a regulatory caution regarding the risk of high potassium levels (hyperkalemia). Official sources state that using potassium supplements is contraindicated. This caution related to hyperkalemia often extends to the consumption of high-potassium foods and salt substitutes, which should be discussed with a healthcare professional.


Q: Does Diocor interact with over-the-counter pain relievers like ibuprofen?

Official warnings specify that Diocor interacts with a class of painkillers known as Non-Steroidal Anti-inflammatory Drugs (NSAIDs), which includes common ingredients like ibuprofen and naproxen. This combination is described in regulatory product information as potentially reducing the medicine's fluid-reducing and blood pressure-lowering effects.


Q: Is it normal to feel dizzy when first starting Diocor?

Dizziness is a common side effect described in regulatory documents. This may be related to changes in fluid volume or blood pressure as the body adjusts to the medicine. The official safety profile includes dizziness under common adverse reactions.


Q: Can Diocor cause tiredness or fatigue?

While tiredness or fatigue is not categorized as a 'Very Common' side effect, the regulatory safety profile does include the possibility of drowsiness and conditions that can lead to feeling unwell, such as dehydration or electrolyte disturbances. These effects may be perceived by users as general tiredness or fatigue.


Q: Can I use Diocor if I have kidney issues?

The medicine is contraindicated (must not be used) in patients with severe renal impairment or anuria (no urine production). For those with existing kidney issues that are not severe, the official regulatory information indicates that the medicine should be used with caution and requires close monitoring of kidney function and electrolytes.


Q: What is the difference between Diocor and other common heart medicines?

Regulatory classification defines Diocor as a combination diuretic, meaning it works primarily on the kidneys to remove excess fluid. This function is distinct from other common heart medicine classes, such as beta-blockers or ACE inhibitors, which affect the heart and blood vessels using different molecular mechanisms.


Q: Is Diocor known to affect sleep?

Official administration instructions state that the final dose of the day must not be taken in the late afternoon or evening. This timing instruction is given specifically to help prevent sleep disruption due to the expected increase in urination caused by the medicine.


Q: What should I do if a side effect of Diocor seems serious?

Official guidance describes the need for prompt medical attention if symptoms occur that may indicate a serious reaction. Examples of such serious, though rare, events include signs of a severe allergic reaction, severe stomach pain, or unexplained bleeding or bruising.


Q: What is the role of Diocor in managing chronic conditions?

Diocor is indicated for managing fluid overload in certain chronic conditions such as Chronic Heart Failure and Liver Cirrhosis. Its role, according to official documents, is to help maintain fluid and electrolyte balance over time to lessen the physical strain resulting from fluid retention.


Q: What kind of research has been done on Diocor?

Research supporting the use of the combination has included studies such as Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies primarily focus on clinical outcomes related to managing fluid volume, such as monitoring changes in hospitalization rates and overall functional status of patients.


Q: Does Diocor interact with alcohol?

Regulatory information warns that alcohol may have additive effects with Diocor in lowering blood pressure. This combination is described as potentially increasing the risk of side effects such as dizziness or fainting.


Q: Can Diocor cause weight changes?

The drug's primary action is to cause the loss of excess water and sodium, which results in a reduction of total fluid volume. Consequently, a reduction in body weight is commonly observed and related to fluid loss.


Q: How can I tell if Diocor is helping my condition?

Observed clinical endpoints in studies include reductions in fluid congestion or swelling (edema). Additionally, regular clinical monitoring, such as checking blood pressure, kidney function, and electrolytes, is described as a necessary part of the treatment to assess the drug's effect.


Q: How does Diocor help the heart work more efficiently?

The regulatory rationale explains that the medicine works by promoting the elimination of excess fluid and sodium from the body. This reduction in total fluid volume lessens the overall physical and circulatory strain on the heart, which is intended to lessen the physical and circulatory strain.


Q: What is the typical age range of people who take Diocor?

The fixed-dose product is not suitable for use in children. The typical population is adults. Specific warnings are provided for older adults, who may require a lower initial dose and careful monitoring due to their increased susceptibility to side effects.


Q: What is the difference between a common side effect and a serious one for Diocor?

Regulatory documents categorize side effects based on how often they occur in clinical data. Very Common and Common effects are generally minor. Rare or Infrequent effects, such as a severe allergic reaction or severe electrolyte imbalance, represent the serious events that require immediate medical attention.


Q: Does Diocor affect blood sugar levels?

The regulatory safety profile for the furosemide component advises caution for diabetic patients, as it may be associated with changes in blood sugar levels or insulin requirements.


Q: Does Diocor affect cholesterol levels?

Regulatory data for the furosemide component indicates that serum cholesterol and triglyceride levels may rise during treatment. This effect is often temporary, with levels typically returning to normal within six months.


Q: What is the recommended approach if I am scheduled for surgery while taking Diocor?

Perioperative guidance, based on official information, indicates that this medicine is often continued, though individual management decisions must be made by a healthcare professional. It is also noted that any electrolyte abnormalities should be corrected before the procedure.

How should Diocor be stored and disposed of?

How to Store and Dispose of Diocor?

Diocor (Furosemide/Spironolactone) must be stored strictly according to regulatory mandates to ensure its stability.

Required Storage Conditions

The tablets must be maintained at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product requires protection from excess heat, moisture, and sunlight and should not be stored in humid areas like a bathroom.

Container and Child Safety

Diocor must be kept in its original container, and the container must be kept tightly closed to protect the tablets. All medication must be stored out of the sight and reach of children.

Official Disposal Protocol

Unused or expired Diocor should not be kept. Disposal must align with local pharmaceutical waste requirements. Medication must not be flushed down the toilet or poured into a drain unless specific guidance authorizes it, to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diocor found in:

A-Z Index: